- Home
- MERC vs ADCT Comparison
MERC vs ADCT Comparison
Compare MERC & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MERC
- ADCT
- Stock Information
- Founded
- MERC 1968
- ADCT 2011
- Country
- MERC Canada
- ADCT Switzerland
- Employees
- MERC N/A
- ADCT N/A
- Industry
- MERC Paper
- ADCT Biotechnology: Pharmaceutical Preparations
- Sector
- MERC Basic Materials
- ADCT Health Care
- Exchange
- MERC Nasdaq
- ADCT Nasdaq
- Market Cap
- MERC 271.5M
- ADCT 241.0M
- IPO Year
- MERC 1987
- ADCT 2020
- Fundamental
- Price
- MERC $3.58
- ADCT $3.09
- Analyst Decision
- MERC Hold
- ADCT Strong Buy
- Analyst Count
- MERC 3
- ADCT 5
- Target Price
- MERC $5.33
- ADCT $7.75
- AVG Volume (30 Days)
- MERC 707.8K
- ADCT 694.8K
- Earning Date
- MERC 05-01-2025
- ADCT 05-14-2025
- Dividend Yield
- MERC 8.37%
- ADCT N/A
- EPS Growth
- MERC N/A
- ADCT N/A
- EPS
- MERC N/A
- ADCT N/A
- Revenue
- MERC $1,996,904,000.00
- ADCT $75,817,000.00
- Revenue This Year
- MERC $2.43
- ADCT $9.19
- Revenue Next Year
- MERC $6.12
- ADCT $16.27
- P/E Ratio
- MERC N/A
- ADCT N/A
- Revenue Growth
- MERC N/A
- ADCT 10.49
- 52 Week Low
- MERC $3.20
- ADCT $1.05
- 52 Week High
- MERC $9.78
- ADCT $4.13
- Technical
- Relative Strength Index (RSI)
- MERC 34.30
- ADCT 79.62
- Support Level
- MERC $3.47
- ADCT $1.83
- Resistance Level
- MERC $4.22
- ADCT $2.35
- Average True Range (ATR)
- MERC 0.17
- ADCT 0.30
- MACD
- MERC 0.03
- ADCT 0.13
- Stochastic Oscillator
- MERC 14.67
- ADCT 98.92
About MERC Mercer International Inc.
Mercer International Inc is a forest products company with two reportable operating segments in pulp and solid wood. The pulp segment consists of the manufacture, sale, and distribution of pulp, electricity, and chemicals. The company has a geographical presence in the USA, Germany, China, and Other countries, where the majority of revenue is generated from the USA. The majority of the revenue is generated from the Pulp segment.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).